CEA、CA125和CA153联合检测在小细胞肺癌诊断中的应用

Application of combined determinant of CEA,CA125 and CA153 in the diagnosis of small cell lung cancer

目的探讨CEA、CA125和CA153三种肿瘤标志物联检在小细胞肺癌诊治中的应用前景。方法采用化学发光免疫分析法分别测定50例小细胞肺癌和22例肺良性疾病患者血清中CEA、CA125和CA153水平。结果小细胞肺癌患者血清中CEA为(8.18±13.84)ng/ml,CA125为(65.13±9.97)ng/ml,CA153为(16.73±9.77)ng/ml,均显著高于肺良性疾病组的血清水平(P<0.05)。三项标志物对小细胞肺癌诊断的敏感性分别为32%、54%、18%;两两联检之后CEA/CA125、CEA/CA153、CA125/CA153的敏感性分别为70%、50%、64%;而三项联检对小细胞肺癌的敏感性达80%,特异性100%。结论联合检测CEA、CA125和CA153三项标志物可有效提高小细胞肺癌诊断的敏感性。

Objective To explore the clinical value of combined determination of serum CEA,CA125 and CA153 levels in the diagnosis of Small Cell Lung Cancer（SCLC）.Methods The serum CEA,CA125 and CA153 levels were detected in 50 patients with SCLC and 22 patients with benign lung diseases by chemiluminescence immunoassay.Results The results showed that the levels of CEA,CA125 and CA153 in SCLC patients were 8.18±13.84 ng/ mL,65.13±9.97 ng/ mL,16.73±9.77 ng/ mL.They were significantly higher than those in benign lung diseases patients（P〈0.05）.The sensitivity of CEA,CA125 and CA153 were 32 %,54 % and 18 % respectively.The sensitivity of combined determination of CEA/CA125,CEA/CA153,CA125/CA153 was 70%,50% and 64% respectively.The sensitivity of combined determination of CEA,CA125,CA153 was 80%.Conclusion The combined determination of CEA,CA125 and CA153 could significantly improve the sensitivity and specificity of the diagnosis of SCLC.